fbpx

QQQ
+ 0.35
372.63
+ 0.09%
BTC/USD
+ 417.52
43228.09
+ 0.98%
DIA
+ 0.36
347.20
+ 0.1%
SPY
+ 0.78
442.40
+ 0.18%
TLT
-1.45
149.81
-0.98%
GLD
-0.19
163.70
-0.12%

Why BofA Has Low Expectations For Gilead's Remdesivir As Potential Coronavirus Treatment

March 20, 2020 2:52 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Why BofA Has Low Expectations For Gilead's Remdesivir As Potential Coronavirus Treatment

Gilead Sciences, Inc. (NASDAQ:GILD) shares spiked about 6.6% Wednesday in reaction to a Piper Sandler note that suggested the biopharma's remdesivir could be approved for COVID-19. 

An analyst at BofA Securities isn't convinced of remdesivir's potential.

The Gilead Analyst

Analyst Geoff Meacham maintained a Neutral rating on Gilead with a $70 price target.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

The Gilead Thesis

Gilead's remdesivir is the only COVID-19 treatment that is in late-stage development, with a potential readout in April, Meacham said in a Friday note. (See his track record here.)

While the drug is likely to have some activity, the overall clinical benefit in COVID-19 patients could be modest, the analyst said, citing infectious disease specialists with experience in viral respiratory disease.

The key opinion leaders BofA interviewed highlighted difficulties such as a high placebo effect, a high bar for efficacy in severe patients, existing lung/tissue damage and challenges with optimizing the best time of therapy in mild/moderate patients, he said. 

The BofA contacts also felt remdesivir could face challenges in adoption, as it needs to be administered intravenously over 10 days in a hospital setting and by caregivers who are already burdened by the epidemic, Meacham said. 

"While we recognize the urgent need for effective COVID-19 therapies, we are not optimistic on remdesivir." 

"Net-net, we don't view the probability of success in the two trials in China as particularly high for Gilead's remdesivir," he added.

The analyst said he favors other modalities such as vaccines and antibodies that are likely to be more effective and specific.

Pivotal data supporting approval for Gilead is unlikely to be released until the first half of 2021, according to BofA. 

Gilead Price Action

The stock was down 5.64% at $74.12 at the time of publication Friday. 

Related Links:

The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company

The $10, 10-Minute COVID-19 Test Sending Biomerica Soaring 600% In 2 Days

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Gilead Analysts Trim Expectations After 'Very Unexpected' Adverse FDA Ruling

Gilead Analysts Trim Expectations After 'Very Unexpected' Adverse FDA Ruling

Gilead Sciences, Inc. read more
Gilead Analyst Questions Remdesivir's Ultimate Upside As Study Begins For Inhaled Version

Gilead Analyst Questions Remdesivir's Ultimate Upside As Study Begins For Inhaled Version

Gilead Sciences, Inc. read more
Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Gilead Analysts Tackle Early Results From Remdesivir Study In COVID-19, Morgan Stanley Says Stock Move Looks Overdone

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 thera read more
Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use

Gilead Analysts Break Down Remdesivir Data Readout From Compassionate Use

Gilead Sciences, Inc. read more